AbbVie's post-Humira stalwarts Skyrizi, Rinvoq performing exactly as hoped, CEO says

AbbVie is relying on its next-gen immunology drugs Skyrizi and Rinvoq to fill what will be a massive sales gap once blockbuster Humira faces generic foes in the U.S. And as the company sees it, everything is going according to plan.